Neuland Laboratories [NEULANDLAB] vs Alembic [APLLTD] Detailed Stock Comparison

Neuland Laboratories Ltd.

NSE
Loading...

Alembic Pharmaceuticals Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Neuland Laboratories Ltd. wins in 12 metrics, Alembic Pharmaceuticals Ltd. wins in 8 metrics, with 0 ties. Neuland Laboratories Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Neuland Laboratories Ltd. Alembic Pharmaceuticals Ltd. Better
P/E Ratio (TTM) 103.42 23.42 Alembic Pharmaceuticals Ltd.
Price-to-Book Ratio 11.41 2.77 Alembic Pharmaceuticals Ltd.
Debt-to-Equity Ratio 16.33 28.00 Neuland Laboratories Ltd.
PEG Ratio -1.72 -1.77 Neuland Laboratories Ltd.
EV/EBITDA 347.81 14.29 Alembic Pharmaceuticals Ltd.
Profit Margin (TTM) 2.29% 8.66% Alembic Pharmaceuticals Ltd.
Operating Margin (TTM) 12.10% 11.37% Neuland Laboratories Ltd.
EBITDA Margin (TTM) 12.10% 11.37% Neuland Laboratories Ltd.
Return on Equity 17.06% 11.24% Neuland Laboratories Ltd.
Return on Assets (TTM) 11.93% 7.51% Neuland Laboratories Ltd.
Free Cash Flow (TTM) $1.11B $-4.76B Neuland Laboratories Ltd.
Dividend Yield 0.08% 1.09% Alembic Pharmaceuticals Ltd.
1-Year Return 30.36% -25.60% Neuland Laboratories Ltd.
Price-to-Sales Ratio (TTM) 30.51 2.03 Alembic Pharmaceuticals Ltd.
Enterprise Value $185.79B $161.16B Neuland Laboratories Ltd.
EV/Revenue Ratio 30.67 2.22 Alembic Pharmaceuticals Ltd.
Gross Profit Margin (TTM) 44.60% 71.81% Alembic Pharmaceuticals Ltd.
Revenue per Share (TTM) $515 $371 Neuland Laboratories Ltd.
Earnings per Share (Diluted) $139.29 $32.07 Neuland Laboratories Ltd.
Beta (Stock Volatility) -0.32 0.34 Neuland Laboratories Ltd.

Neuland Laboratories Ltd. vs Alembic Pharmaceuticals Ltd. Stock Performance Analysis

Loading Price Chart...

NEULANDLAB
APLLTD

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Neuland Laboratories Ltd.-0.83%0.54%2.81%39.46%3.75%13.25%
Alembic Pharmaceuticals Ltd.-0.75%-1.04%-5.91%9.25%-14.68%-11.93%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Neuland Laboratories Ltd.30.36%489.12%756.32%2,077.38%16,439.72%20,028.75%
Alembic Pharmaceuticals Ltd.-25.60%20.70%-23.84%41.04%1,498.60%1,498.60%

Performance & Financial Health Analysis: Neuland Laboratories Ltd. vs Alembic Pharmaceuticals Ltd.

MetricNEULANDLABAPLLTD
Market Information
Market Cap i₹184.81B₹147.63B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i33,18175,949
90 Day Avg. Volume i39,837103,405
Last Close₹17,056.00₹737.75
52 Week Range₹11,500.00 - ₹19,747.00₹635.80 - ₹1,107.90
% from 52W High-13.63%-33.41%
All-Time High₹19,747.00 (Nov 10, 2025)₹1,303.90 (Oct 07, 2024)
% from All-Time High-13.63%-43.42%
Growth Metrics
Quarterly Revenue Growth0.11%0.11%
Quarterly Earnings Growth-0.60%-0.04%
Financial Health
Profit Margin (TTM) i0.02%0.09%
Operating Margin (TTM) i0.12%0.11%
Return on Equity (TTM) i0.17%0.11%
Debt to Equity (MRQ) i16.3328.00
Cash & Liquidity
Book Value per Share (MRQ)₹1,262.78₹270.70
Cash per Share (MRQ)₹131.49₹7.27
Operating Cash Flow (TTM) i₹3.44B₹-3,101,700,000
Levered Free Cash Flow (TTM) i₹2.60B₹5.83B
Dividends
Last 12-Month Dividend Yield i0.08%1.09%
Last 12-Month Dividend i₹12.00₹11.00

Valuation & Enterprise Metrics Analysis: Neuland Laboratories Ltd. vs Alembic Pharmaceuticals Ltd.

MetricNEULANDLAB (Apr 26, 2026)APLLTD (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i103.4223.42
Forward P/E i42.6017.75
PEG Ratio i-1.72-1.77
Price to Sales (TTM) i30.512.03
Price to Book (MRQ) i11.412.77
Market Capitalization
Market Capitalization i₹184.81B₹147.63B
Enterprise Value i₹185.79B₹161.16B
Enterprise Value Metrics
Enterprise to Revenue i30.672.22
Enterprise to EBITDA i347.8114.29
Risk & Other Metrics
Beta i-0.320.34
Book Value per Share (MRQ) i₹1,262.78₹270.70

Financial Statements Comparison: Neuland Laboratories Ltd. vs Alembic Pharmaceuticals Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricNEULANDLAB (2025)APLLTD (2025)
Revenue/Sales i14.34B65.40B
Cost of Goods Sold i7.51B21.37B
COGS % of Revenue i52.3%32.7%
Gross Profit i6.84B44.03B
Gross Margin i47.7%67.3%
Research & Development iN/A96.00M
Operating Income (EBIT) i2.67B7.35B
Operating Margin i18.6%11.2%
EBITDA i3.41B10.52B
EBITDA Margin i23.8%16.1%
Pre-Tax Income i3.46B7.07B
Pre-Tax Income % of Revenue i24.1%10.8%
Income Tax i862.21M1.25B
Income Tax % of Revenue i6.0%1.9%
Net Income (Profit) i2.60B5.82B
Profit Margin i18.1%8.9%

Balance Sheet & Liquidity Metrics

MetricNEULANDLAB (2025)APLLTD (2025)
Cash & Equivalents i1.32B834.80M
Total Current Assets i11.39B40.88B
Total Current Assets % of Revenue i79.4%62.5%
Total Current Liabilities i4.66B24.12B
Total Current Liabilities % of Revenue i32.5%36.9%
Long-Term Debt i1.09B467.70M
Long-Term Debt % of Revenue i7.6%0.7%
Total Shareholders Equity i15.25B51.90B
Retained Earnings i9.95B43.94B
Retained Earnings % of Revenue i69.3%67.2%
Property, Plant & Equipment i6.74B4.45B

Cash Flow Statement Comparison

MetricNEULANDLAB (2025)APLLTD (2025)
Operating Cash Flow i3.44B-3.10B
Operating Cash Flow % of Revenue i24.0%-4.7%
Capital Expenditures i-2.05B-5.54B
Free Cash Flow i1.11B-4.76B
FCF Margin i7.7%-7.3%
Debt Repayment i-394.35MN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricNEULANDLABAPLLTD
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i12.83M196.56M
Float Shares i4.86M57.90M
% Held by Insiders i37.96%70.56%
% Held by Institutions i27.06%16.81%
% Held by Public i34.98%12.63%

Dividend Analysis & Yield Comparison: Neuland Laboratories Ltd. vs Alembic Pharmaceuticals Ltd.

MetricNEULANDLABAPLLTD
Last 12-Month Dividend i₹12.00₹11.00
Last 12-Month Dividend Yield i0.08%1.09%
3-Year Avg Annual Dividend i₹12.00₹13.33
3-Year Avg Dividend Yield i0.20%1.17%
3-Year Total Dividends i₹36.00₹40.00
Ex-Dividend DateJul 18, 2025Jul 29, 2025